…acknowledgment that companies pursuing AI are getting much attention, and there is a fear of missing out (FOMO) in the investment community if one of these AI startups develops a…
…acknowledgment that companies pursuing AI are getting much attention, and there is a fear of missing out (FOMO) in the investment community if one of these AI startups develops a…
…include: Growing Complexity of Medical Devices: One of the biggest challenges in meeting regulatory requirements is the growing complexity of medical devices. This increasing complexity makes it difficult for manufacturers…
…include: Growing Complexity of Medical Devices: One of the biggest challenges in meeting regulatory requirements is the growing complexity of medical devices. This increasing complexity makes it difficult for manufacturers…
…is often where the work starts,” said Unger. “Set a target, communicate it companywide, and hold yourself accountable. One option is to create incentives.” Procurement Companies can commit to green…
…is often where the work starts,” said Unger. “Set a target, communicate it companywide, and hold yourself accountable. One option is to create incentives.” Procurement Companies can commit to green…
…years ago. With these advances, one commonly overlooked layer in the early stages of device development is the stick-to-skin adhesive. The Challenge of Sticking to Skin Ask a pressure sensitive…
…years ago. With these advances, one commonly overlooked layer in the early stages of device development is the stick-to-skin adhesive. The Challenge of Sticking to Skin Ask a pressure sensitive…
…providers to ensure patient safety even when healthcare personnel are not present. There are many different automated patient monitoring systems in development today. For example, researchers have applied AI computer…
…providers to ensure patient safety even when healthcare personnel are not present. There are many different automated patient monitoring systems in development today. For example, researchers have applied AI computer…
…80% documentation and 20% testing. CSA also encourages companies to use vendor documentation to reduce testing burdens. To ensure a reliable validation outcome, FDA guidelines recommend defining a test strategy…
…80% documentation and 20% testing. CSA also encourages companies to use vendor documentation to reduce testing burdens. To ensure a reliable validation outcome, FDA guidelines recommend defining a test strategy…
…interested parties in the medical products development community, such as pharmaceutical companies, ethicists, academia, patients and patient groups, and global counterpart regulatory and other authorities, on using AI/ML in drug…
…interested parties in the medical products development community, such as pharmaceutical companies, ethicists, academia, patients and patient groups, and global counterpart regulatory and other authorities, on using AI/ML in drug…
…event of a research-related injury. It should also describe who will have access to the trial participant’s personal health information obtained during the DCT. Stakeholders can submit comments on the…
…event of a research-related injury. It should also describe who will have access to the trial participant’s personal health information obtained during the DCT. Stakeholders can submit comments on the…
…more complex information and highlight critical safety information. But, of course, it is not always possible to communicate all facets of intended use via design affordances, especially for more complex…
…more complex information and highlight critical safety information. But, of course, it is not always possible to communicate all facets of intended use via design affordances, especially for more complex…
…neurovascular, the most common device used is a coil, where you can go in and choke off in aneurysm or a tumor, and there are a lot of small components…
…neurovascular, the most common device used is a coil, where you can go in and choke off in aneurysm or a tumor, and there are a lot of small components…
